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score between the 2 groups. Kaplan-Meier plots of the proba-
bility of withdrawal as a result of disease progression did not
differ between the 2 groups.
The mean change in total UPDRS score remained within
3 points in the 2 groups. This deterioration in total UPDRS
score was lower than those in the placebo groups in other trials
(DATATOP study: 24th month, 14.025; QE3 trial: 16th month,
6.926). It has been reported that patients with PD drink a smal-
ler amount (341 ± 209 mL) of water per day than those without
PD. In the present study, all participants drank 1,000 mL of test
water per day, although drinking the water was not sufficient to
cause disease improvement.
The study limitations were that patients in the prodromal,
very early PD, or progressed PD stages were not enrolled and
that the UPDRS scores in the “off” phase were not evaluated.
The concentration of H2 (measured via oxidation reduction
potential method using ENH-1000 [Trustlex Inc., Osaka,
Japan]) in the placebo water in the “Hydrogen 7.0” kits used
previously was identical to that in the bottles containing H2
water (0.16 ± 0.16 ppm; n = 30). This concentration was
considered sufficiently low for the water to act as a placebo.
This study revealed that the consumption of H2 water was
safe, but did not show beneficial effects in patients with
PD. Further development and application methods will be
required to accelerate effective treatments for PD.
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Swimming is a common activity, practiced by both healthy
and nonhealthy people of all ages. It is a complex activity that
requires coordination of breathing with continued and har-
monic upper and lower limb movements.1 Because of the
unique properties of water, aquatic activities are usually asso-
ciated with facilitated movements and therapeutic properties.2
Parkinson’s disease (PD) presents with asymmetric motor
features that usually interfere with complex activities.3
Aquatic therapy is usually considered enjoyable and associ-
ated with health benefits in PD patients.2 However, although
scarce, there is a growing amount of data suggesting swim-
ming difficulties after disease onset. Several reports of patients
in Internet forums mention swimming problems, attributing
them to mobility problems, lack of coordination, and
strength.4
This letter refers to an important finding of an online and
paper-based self-administered questionnaire, conducted in
Portugal and the United Kingdom, to evaluate the frequency
of changes in swimming capacity after PD onset. The study
was approved by the Centro Académico Medicina de Lisboa
(415/16) and the Campus Neurológico Sénior (Ref: 4-2017)
Ethics Committee.
An estimated number of 4300 patients was informed about
the study. Of these, 381 patients responded to the question-
naire, of whom 72 were excluded because of incomplete data.
Participant mean age was 64 years old, with a mean disease
duration of 4 years. Tremor was reported as first complaint
by 44% of the patients (n = 137).
Of 309 collected answers, 90% pf the patients (n = 277)
were able to swim before PD symptom onset. Of those who
were able to swim, 87.7% (n = 243) noticed a change in
swimming performance after disease onset, and 49.1%
(n = 136) reported having had a drowning or near-drowning
episode (Fig. 1). Breathing difficulties during swimming were
described by 36.5% of patients (n = 101), and 39.4%
(n = 109) reported the lower limbs as their main cause of dif-
ficulty. According to participants’ answers, the most frequent
reasons for stopping swimming were difficulties in movements
coordination (n = 71) and floating (n = 57).
Our results show that PD can seriously interfere with swim-
ming capacity, potentially causing major safety risks. A recent
case report describes 4 PD patients with swimming difficulties
or drowning after deep brain stimulation surgery.5 We
hypothesize that PD patients’ swimming difficulties are related
to the asymmetric features, lack of coordination, and diffi-
culty performing complex activities. Mean disease duration of
patients who reported changes in swimming capacity was
6 ± 5.0 years, suggesting an early onset of this difficulty.
However, selection bias for patients more capable of accessing
the Internet or more motivated to take part in a swimming
questionnaire because of previous near-drowning episodes
might have occurred. Also, patients’ selection has been done
based on their assumption of the diagnosis; thereby, it cannot
be excluded that patients with atypical parkinsonism were
included.
We do not advocate that patients stop swimming or doing
aquatic therapy. Instead, we would like to alert to the poten-
tial risks associated with swimming and to draw attention to
the need to understand the disease-related features that con-
tribute to the changes in swimming performance.
Acknowledgments: We thank Associação Portuguesa de Doentes de
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FIG. 1. Frequency and demographic data of PD patients with changes
in swimming capacity and drowning events.
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